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Abstract
Gaucher disease, the most common lysosomal storage disorder, is caused by
mutations in the gene encoding the acid-β-glucosidase lysosomal hydrolase enzyme that 
cleaves glucocerebroside into glucose and ceramide. Reduced enzyme activity and impaired
structural stability arise due to >300 known disease-causing mutations. Several of these
mutations have also been associated with an increased risk of Parkinson disease (PD).
Since the discovery of the acid-β-glucosidase x-ray structure, there have been major 
advances in our understanding of the structural properties of the protein. Analysis of specific
residues has provided insight into their functional and structural importance and provided
insight into the pathogenesis of Gaucher disease and the contribution to PD. Disease-
causing mutations are positioned throughout the acid-β-glucosidase structure, with many 
located far from the active site and thus retaining some enzymatic activity however, thus far
no clear relationship between mutation location and disease severity has been established.
Here, we review the crystal structure of acid-β-glucosidase, while highlighting important 
structural aspects of the protein in detail. This review discusses the structural stability of
acid-β-glucosidase, which can be altered by pH and glycosylation, and explores the 
relationship between known Gaucher disease and PD mutations, structural stability and
disease severity.
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Introduction
Acid-β-glucosidase (GCase) (IUBMB enzyme nomenclature number EC 3.2.1.45) is 
a lysosomal enzyme involved in cleaving the glycolipid glucocerebrosidase (also known as
glucosylceramide or GlcCer) into glucose and ceramide (Brady et al., 1965). Mutations in the
glucocerebrosidase (GBA) gene encoding this enzyme cause Gaucher disease (GD), an
autosomal recessive lysosomal storage disorder (LSD). This results in the lysosomal
accumulation of GlcCer in the macrophages of the reticuloendothelial system as a
consequence of decreased GCase activity or stability. Clinically, GD is associated with
enlarged organs, hepatomegaly, splenomegaly and in a minority of cases a neurological
deficit (Grabowski, 2008). That said there is evidence of a range of neurological involvement
across the entire spectrum of Gaucher disease (Beavan et al., 2015). The disease can be
classified into three clinical subtypes Type 1, Type 2 and Type 3 based upon the severity of
neurological features. Type 1, the most common variant, is non-neuronopathic and can be
asymptomatic with onset at any age. On the other hand, both Type 2 and Type 3 are
neuronopathic. Type 2 GD has severe neurological involvement, with disease onset
occurring in the first few months of life and the disorder rapidly progressing until death during
infancy. Type 3 is a chronic neuronopathic disease, with patients surviving infancy but
having neurological features for the rest of their lives (Sidransky, 2012). Although GD occurs
in the general population with a frequency of approximately 1 in 50,000, prevalence is much
greater among the Ashkenazi Jewish population with the incidence around 1 in 800
(Charrow et al., 2000; Horowitz et al., 1998).
Over 300 mutations have been identified in GD patients including nonsense
mutations, deletions and insertions and complex alleles. The most prevalent are missense
mutations (Beutler et al., 2005; Hruska et al., 2008). Two important disease-causing
missense mutations are N370S and L444P, which account for the majority of mutations
found in the Ashkenazi Jewish population (Sidransky and Lopez, 2012). The N370S
mutation causes a mild Type 1 GD in patients, whereas the L444P mutation results in a
severe neurological disorder, such as Type 2 and 3. Over the past 15 years, it has been
reported that GD may increase the risk for PD, the most common neurodegenerative
movement disorder, with many GD patients developing parkinsonian symptoms (Aharon-
Peretz et al., 2004; Beavan et al., 2015; Bembi et al., 2003; McNeill et al., 2012; Tayebi et
al., 2003).
Normally, native GCase is synthesised on endoplasmic reticulum (ER)-bound
ribosomes and translocated to the ER for correct folding before being transported to the
lysosome. When the protein is mutated, however, it is identified as misfolded and retained in
the ER where it is eliminated by the ubiquitin proteasomal system (UPS), leading to a
reduction in enzyme concentration at the lysosome (Schapira and Gegg, 2013).
Interestingly, when analysed in vitro several mutated GCase variants, including N370S and
L444P, produce stable proteins with residual activity (Alfonso et al., 2004; Liou et al., 2006).
This observation has led to the development of small molecular chaperones, which are
designed to bind the misfolded protein to increase trafficking and reduce degradation and
thus have the potential to offer a therapeutic benefit to GD patients (Jung et al., 2016).
Until the past decade or so, the three-dimensional structure of GCase was poorly
understood. Therefore, exploration of the relationships between mutations, structure,
disease manifestation and enzymatic activity were difficult. The first review of the structure of
GCase was published in 2008 (Kacher et al., 2008), with the first X-ray structure of GCase
elucidated only in 2003 (Dvir et al., 2003). This review focuses on the main structural
aspects of the GCase enzyme and the contribution of current literature to our knowledge of
the protein structure and potential relationships with common GD and PD mutations.
Structure of Acid- β-glucosidase 
Key Structural Features
The mature GCase polypeptide is a glycoprotein consisting of 497 residues (Grabowski
et al., 1990) with a molecular weight between 59-69 kDa depending on post-translational
modification of the protein (Bergmann and Grabowski, 1989). GCase comprises of three
discontinuous domains (Figure 1). Domain I (residues 1-27 and 383-414) consists of an
antiparallel β-sheet flanked by a loop. Within this domain exists two disulphide bridges 
(residues 4-16 and 18-23) which may aid proper folding of the protein (Dvir et al., 2003;
Moharram et al., 2006). Domain II (residues 30-75 and 431-497) is an 8-stranded β-barrel, 
which forms an independent domain to resemble an immunoglobulin (Ig) fold (Lieberman et
al., 2009). The third domain, domain III (residues 76-381 and 416-430) is the catalytic
domain and comprises of a (β/α)8 triosephosphate isomerase (TIM) barrel. Domain III
harbours the active site in addition to having three free cysteines (residues 126, 248 and
342) (Dvir et al., 2003; Moharram et al., 2006). It is thought that these free cysteines and the
cysteines involved in disulphide bond formation in domain I are essential for preservation of
an active enzyme, allowing the breakdown of GlcCer into glucose and ceramide and
preventing substrate accumulation. In particular, Cys 342 is thought to exert important
stabilisation effects due to its close proximity to the active site (Figure 2a) (Liou et al., 2006).
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Figure 1. The X-ray structure of acid-β-glucosidase (PDB code 3GXD) created using PYMOL 
(http://www.pymol.org). Domain I is shown in pink and houses the two disulphide bridges, with the
sulphur atoms depicted by yellow spheres. Domain II is shown in green and is an Ig-like domain.
Domain III, the catalytic domain, is shown in teal and is a TIM barrel structure. This domain contains
the three free cysteines, of which are labelled by orange spheres.
Active Site
The active site is a catalytic dyad, consisting of two important residues Glu 340 and
Glu 235 (Figure 2). Site-directed mutagenesis has revealed Glu 235 is the acid/base catalyst
(Fabrega et al., 2002), with electrospray tandem mass spectrometry identifying Glu 340 as
the nucleophile (Miao et al., 1994). Both residues are located near the c-terminus of β-
strands 4 and 7 in domain III, existing on opposite sides of the glycosidic bonds to be
hydrolysed, approximately 5 Å away from each other. In addition to these two catalytic
residues, several residues that line the active site region are thought to be important
although not directly involved in catalysis (Lieberman, 2011), potentially playing a role in
stabilising the substrate or modulating protonation sites. These include Arg 120, Asp 127,
Phe 128, Trp 179, Asn 234, Tyr 244, Phe 246, Tyr 313, Cys 342, Ser 345, Trp 381, Asn 396,
Phe 397 and Val 398 (Figure 2b & 2c). Of these residues, seven are aromatic and line the
active site pocket (Phe 128, Trp 179, Tyr 244, Phe 246, Tyr 313, Trp 381, Phe 397) with a
potential role in recognising the GlcCer substrate (Chi et al., 1999).
Located at the entrance to the active site are several hydrophobic residues that may
facilitate protein interaction with the lysosomal membrane, helping transport the protein to
the area where activity takes place. These residues may also aid the interaction between
GCase and the activator protein, Saposin C (Wilkening et al., 1998). Saposin C is thought to
associate with the GCase and activate the hydrolysis of GlcCer (Ho and O'Brien, 1971;
Tamargo et al., 2012; Vaccaro et al., 2010). A deficiency in Saposin C levels through
mutations leads to a GD phenotype, most commonly the neurological variants (Vaccaro et
al., 2010). This occurs despite normal GCase protein activity, suggesting if structural
alterations occurred in mutant GCase to ameliorate it’s interaction with Saposin C there may
be a significant reduction in GlcCer hydrolysis and the development of GD. Although the
hydrophobic residues at the entrance to the active site may play some role in GCase binding
of Saposin C, several GCase specific residues have been thought potentially to interact with
Saposin C, including residues 443-445 where the severe L444P mutation is located (Atrian
et al., 2008).
Furthermore, there are several polar residues present in and around the active site.
These residues allow extensive hydrogen bond interactions to stabilise the active site and
hold the substrate in place once bound (Lieberman et al., 2007). Most active site residues
are static but some are sensitive to ligand binding (Tyr 313, Asp 315, Asn 396 and Phe 397)
and have high thermal B-factors (Lieberman, 2011) indicating that these residues can take
on different conformations depending on the substrate bound. The mechanism for substrate
docking utilises double-displacement acid/base chemistry and involves the donation of a
proton from the acid/base Glu 235 residue and the nucleophilic attack of a deprotonated
glucose by Glu 340 to yield a covalent enzyme-glycone intermediate, followed by hydrolysis
(Ketudat Cairns and Esen, 2010).
Figure 2. The X-ray structure of acid-β-glucosidase active site (PDB code 3GXD) created using 
PYMOL (http://www.pymol.org). (A) Domain I is coloured pink, with the sulphur atoms involved in the
disulphide bridges labelled as yellow spheres. Domain II is coloured green. Domain III is coloured teal
and the three free cysteines are depicted by orange spheres. The active site catalytic residues Glu235
and Glu340 are shown as ball-and-stick models. (B) The active site residues. The catalytic residues
are shown as ball-and-stick models and the residues lining the active site are presented as stick
models. (C) Stick-model representation of residues lining the active site. The catalytic dyad is shown
as ball-and-stick models. Hydrogen bonds are shown as black dashed lines.
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pH stability and important loop structures
An enzyme’s pH stability is an essential property closely related to enzymatic
conformation, structural stability and catalytic activity (Xia et al., 2016). The optimal pH for
GCase activity is round 4.7 – 5.9 (Lieberman et al., 2007; Liou et al., 2006; Tan et al., 2014),
which is consistent with its lysosomal function. Interestingly, a bimodal peak in activity
across a range of pH conditions has been reported (Carroll, 1981; Michelin et al., 2004;
Raghavan et al., 1980). This may be due to the existence of two GCase isozymes each with
the same biological function but altered molecular structures and pH kinetics (Michelin et al.,
2004). At neutral pH (~7.4), similar to that of the ER, enzymatic activity is abolished
(Lieberman et al., 2007). This may be through structural changes in acidic environments or
changes in the protonation of active site residues. Another possible explanation is that at low
lysosomal pH GCase exhibits increased association with Saposin C (Zhao et al., 2014),
suggesting there may be some structural alteration to the Saposin C binding site away from
the active site, but further investigation is required.
Several loops have been detected in GCase structure. The most prominent of these
loops are loop 1 (residues 345-349), which is rich in hydrophobic residues, loop 2 (residues
394-399) and loop 3 (residues 312-319) (Premkumar et al., 2005), all of which cap the active
site (Figure 3a). All loops are mobile and have some degree of flexibility, adopting varying
conformations with respect to each other (Kacher et al., 2008).
Loops 1 and 3 are located at the mouth of the active site (Figure 3a) and it is the
configurations of these structures that affect the active site shape (Offman et al., 2011). Both
exhibit high thermal B-factors indicating they are mobile in both acidic and neutral pH
environments, and are likely to be adopting several conformations (Brumshtein et al., 2007;
Brumshtein et al., 2010; Lieberman et al., 2009; Offman et al., 2010), suggesting the active
site residues are not pre-organised for substrate binding. Using GCase inhibitors, such as
isofagomine, to bind to the structure across different pH’s (4.5 - 7.5) has indicated the
potential importance of these loops in GlcCer binding. A substantial rearrangement of loop 3
from an extended loop conformation to a helical formation adjacent to the active site was
observed at acidic conditions, much like the lysosomal environment (Lieberman et al., 2009;
Lieberman et al., 2007). This mechanism causes a new surface topology to be created,
including two hydrophobic grooves to extend from the (β/α)8 TIM barrel in domain III, which
can bind to the alkyl chains of GlcCer (Lieberman et al., 2009). The conformational changes
detected in loop 3 arise in conjunction with changes in the β-sheet structure of residues 341-
344, which are adjacent to the Glu 340 catalytic nucleophile residue, in addition to side-chain
flips of Trp 312 and Trp 378, all associated with the transition of loop 3 into a helical
structure (Brumshtein et al., 2006). A shift in loop 1 upon inhibitor binding was also observed
in acidic pH when compared to neutral pH, resulting in altered hydrogen bond patterns
between the residues at the base of loop 1 and loop 3 near the active site (Lieberman et al.,
2007). However further studies are required to establish whether this change was due to a
higher pH or simply from the presence of water in the active site, or crystal packing.
The hydrogen bonding network is changed at acidic pH through alterations in
protonation of GCase residues. At optimal pH conditions for beta-glucosidases, the
hydrogen bond interaction between the nucleophilic Glu 340 residue and the substrate
oxygen occurred at a much higher abundance, (Flannelly et al., 2015), and may contribute to
the increased enzymatic activity observed. Normally, the GCase active site is too small to
accommodate the GlcCer substrate. At neutral pH residue Tyr 313 is bound via hydrogen
interactions with Glu 325 and acts as a gate to keep the active site closed off. When the
substrate binds to GCase, at lysosomal pH, Tyr 313 changes conformation to bind to Glu
340 in the active site. This change disrupts the hydrogen bonding pattern of the Asp 315
residue, allowing loop 3 to take on the helical conformation and inducing the opening of the
active site. The structure becomes wider and shallower, indicating a possible induced-fit
mechanism for GCase when in close proximity with the active site (Kacher et al., 2008;
Lieberman, 2011; Lieberman et al., 2009). Another important residue is Asn 370, which is
located at the interior of GCase (Figure 3b). Asn 370 is thought to be involved in stabilising
the configuration of loop 3 in its helical conformation at low pH (Grace et al., 1994;
Lieberman et al., 2007), through new hydrogen bond interactions with Trp 312 (Figure 3b)
(Offman et al., 2011).
In addition to a role in substrate docking, it is thought that the flexible loops (loop 2
and 3) are responsible for GCase’s membrane interaction, and may insert into the
membrane bilayer (Yap et al., 2015), with loop 2 interacting with the phosphate heads of the
membrane (Brumshtein et al., 2006). Moreover, as previously mentioned, two disulphide
bridges exist in the GCase structure between residues Cys 4 and Cys 16 and residues Cys
18 and Cys 23. These bridges are in fact located on loop 3, with mutations in these residues
causing marked reductions in catalytic activity (Liou et al., 2006; Premkumar et al., 2005),
indicating the further importance of this loop in enzymatic activity and hydrolysis of GlcCer.
Figure 3. Loops in the X-ray structure of acid-β-glucosidase (PDB code 3GXD) created using PYMOL 
(http://www.pymol.org).. (A) Loops 1, 2 and 3 are labelled by black pointed arrow and coloured pink,
capping the active site. The catalytic dyad is shown as a ball-and-stick model. (B) Loops and
important residues at pH 4.5 (PDB code 3GXD). The loops are coloured pink and labelled by black
pointed arrows. The residues involved in the transition of loop conformations are labelled and shown
as stick models. The catalytic dyad is shown as a stick model. Hydrogen bonds are depicted by
dashed lines.
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Glycosylation
The mature human GCase protein has five potential N-glycosylation sites (Asn 19,
Asn 59, Asn 146, Asn 270 and Asn 462) (Figure 4) with the first four normally occupied
(Berg-Fussman et al., 1993). The GCase enzyme is synthesised as a typical secretory
protein and undergoes co-translational glycosylation modifications during transit through the
Golgi (Leonova and Grabowski, 2000), resulting in a sialylated complex-type structure of 66-
69 kDa (Novo et al., 2010). As macrophages, which are the cells most heavily involved in
GD, internalise GCase through their mannose receptor, the process of glycosylation is
thought to be a key factor for enzyme functionality (Tekoah et al., 2013). This is supported
by the observation that the extensive glycosylation remodelling seen in native GCase
processing is insufficient or absent in fibroblasts derived from GD (Bergmann and
Grabowski, 1989). Moreover, the secretion of GCase is a glycosylation-dependant process
(Leonova and Grabowski, 2000). N-glycosylation generally confers structural stability of the
glycoprotein to which they are attached, increasing plasma residence time and providing
steric protection from non-specific interactions and proteases (Pol-Fachin et al., 2016). In
fact, the development of a catalytically active GCase enzyme is dependent upon N-
glycosylation (Grace and Grabowski, 1990), with occupancy of Asn 19 required for proper
functionality of the catalytic dyad (Berg-Fussman et al., 1993). Site-directed mutagenesis
also revealed an important role for Asn146 in maintaining GCase thermostability, with Asn
270 and Asn 462 mutants exhibiting low activity due to their proximity to the active site
(Berg-Fussman et al., 1993). Further supporting a link between catalysis formation and
glycolysis, it was discovered that the residues around the active site are much more
disordered in the deglycosylated GCase X-ray structure compared to the glycosylated
protein (Liou et al., 2006).
Interestingly, N-glycosylation is thought to have no key role in overall GCase
structure stability but instead affects specific regions of the enzyme to induce local
conformational stability, sometimes in residues far from the site of glycosylation. Presence of
Asn 19 glycosylation stabilises regions 438-445, which is the region where a common GD
mutation (L444P) occurs. Occupation at this site also lowers the RMSD (root-mean-squared
deviation) values for Glu 235 and Glu 340 (Pol-Fachin et al., 2016), suggesting they are in
closer proximity, perhaps improving the stability of the catalytic dyad. Glycosylation at the
site of Asn 59 increases stability in residues 49-69 and reduces motility at residues 136-156.
There is also reduced flexibility in the region around Asn 270 when occupied, however this is
only significantly when the other glycosylation sites are occupied (Pol-Fachin et al., 2016).
No major conformational changes have been observed in different GCase glycoforms with
varied glycosylation content and enzymatic activity remains similar across these glycoforms
(Pol-Fachin et al., 2016) and when comparing the three commercially available recombinant
GCase enzymes (taliglucerase alpha, imiglucerase and velaglucerase alpha) (Tekoah et al.,
2013). As these varied mannose chain lengths and different degrees of glycosylation site
occupancy do not affect catalytic activity it indicates that glycosylation is instead responsible
for influencing GCase structure, stability and flexibility.
Taking this into account, it can be predicted that targeting the glycosylation pathway
may be a potential therapeutic strategy. As mentioned earlier, mutant GCase enzymes
maintain some activity (Alfonso et al., 2004; Grace et al., 1994; Liou et al., 2006), suggesting
that poor structural stability may play a bigger role. It may be worth investigating whether
increasing GCase glycosylation can positively affect conformational stability in mutants.
Figure 4. N-glycosylation sites in x-ray structure of acid-β-glucosidase (PDB code 3GXD) 
created using PYMOL (http://www.pymol.org).. N-glycosylation sites are presented as blue
spheres. The active site catalytic dyad is shown as a ball-and-stick model.
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Quaternary structure
It remains unclear as to how GCase exists in vivo, with its quaternary structure not fully
understood. As mentioned above, the GCase protein has a molecular weight around 59-69
kDa (Bergmann and Grabowski, 1989). SDS-PAGE and radiation inactivation analysis of
isolated GCase protein have been used intensely to try and understand the structure of
GCase, but have produced contradicting results. Isolated splenic GCase revealed bands
corresponding to approximately 60-70 kDa suggesting the protein exists in a monomeric
structure and heterogeneity of glycosylation contributes to the varied molecular weights
(Liedtke and Legler, 1988; Maret et al., 1983). During the same decade or so however, wild-
type GCase isolated from human skin fibroblasts was found to have inactivation values of
approximately double the molecular weight of one GCase protein suggesting a dimeric form
exists (Choy et al., 1986; Dawson and Ellory, 1985; Pentchev et al., 1973). Studies also
indicate that the protein exists in a tetrameric structure with four catalytically active subunits,
when isolated from the human placenta (Pentchev et al., 1973; Strasberg and Lowden,
1983). It must be noted however, that the presence of the Beta-Glucosidase 2 protein, a
non-lysosomal glucosylceramidase encoded by the GBA2 gene, may contribute to these
results. GBA2 encodes a protein of approximately 105 kDa (Cowart, 2011), thus this may
explain the large variations observed. However, if this is not the case these results suggest
that the quaternary structure of GCase in vivo may be tissue specific. The protein may also
have different quaternary structures in GD as GCase protein isolated from type 2 and 3 GD
human fibroblasts have been reported to have a molecular weight consistent with a dimeric
protein (Choy et al., 1986), or 1.5-2-times greater than monomeric when type 1 GD human
GCase was isolated from both fibroblasts (Choy et al., 1986; Maret et al., 1983). This
suggests that mutant type I GCase may exist as an aggregate or a larger functional enzyme.
Perhaps subunit interaction is required for biological activity and mutations in type I GD may
lead to oligomerisation of the mutant protein preventing activity for any associated GCase
subunits. In these studies, mutations were not genotyped so it would be interesting to
investigate if specific point mutations lead to varied changes in the quaternary structure of
GCase.
Acid-β-glucosidase mutations, Gaucher disease and Parkinson 
disease
Over 300 disease-causing mutations have been identified in the GBA gene, with four
specific mutations (N370S, L444P, 84GG and IVS2+1g > a) accounting for approximately
90% of the disease alleles seen in Ashkenazi Jews (Alfonso et al., 2007; Grabowski and
Horowitz, 1997). Different mutations result in a spectrum of GD. The N370S variant is a type
1 non-neuronopathic disorder associated with clinical heterogeneity, presenting a wide range
of symptom severity. Mutations that result in the Type 2 acute neuronopathic GD cause early
onset and death within days to years and rapidly progressive neurological complications.
Those that cause chronic neuronopathic Type 3 GD can result in a range of different severe
phenotypes from myoclonic epilepsy to cardiac abnormalities and learning disabilities
(Sidransky and Lopez, 2012). Mutations in the GBA gene are also the most significant risk
factor for PD, with N370S and L444P mutations the most prevalent. According to a meta-
analysis in 2009, these mutations represent approximately 50% of all GBA mutations found
from genotyping PD patients (Sidransky et al., 2009). N370S alone is reportedly the most
prevalent mutation in GD patients with early-onset parkinsonian (Tayebi et al., 2003).
Interestingly, mild and severe GBA mutations differentially effect the risk of GD patients
developing PD. Severe mutation variants have a greater risk of PD and earlier age of onset
(Gan-Or et al., 2015). As mentioned, L444P mutations result in a severe clinical phenotype
in Type 2 and 3 GD, and these patients are at a much higher risk of developing PD
(Sidransky et al., 2009). The reason that different mutations have differential severity, age of
onset and risk of PD is yet to be elucidated. A hypothesis could be that the different
mutations lead to different conformational changes in the protein structure, however the
relationship between mutation location and disease severity has still not yet been defined.
GBA mutations lead to PD with an earlier onset, faster progression and more
cognitive dysfunction compared to sporadic PD (Neumann et al., 2009). To date, no clinical
correlation between GBA mutations, the levels of GCase activity and GD and PD has been
observed, suggesting there may be another element involved, possibly structural
consequences of the mutations. In patients carrying the GBA mutation, either homozygous,
biallelic or heterozygous, GCase activity was significantly lower than non-carriers, with
homozygous and biallelic patients having the lowest activity (Alcalay et al., 2015). Similarly,
in both CSF and post-mortem brain studies PD patients had reduced activity (Gegg et al.,
2012; Parnetti et al., 2014), however no correlation between the different GBA mutations and
activity was found. In sporadic PD brains GCase activity and protein levels are also reduced
(Gegg et al., 2012), which correlated with regions of increased α-synuclein (Murphy et al., 
2014). This suggests that a loss of activity may contribute to the pathogenesis of PD. In GD,
GCase activity is normally 10-20% with carriers retaining approximately 50% activity
compared to control (Migdalska-Richards and Schapira, 2016). As both homozygous and
heterozygous GBA mutation carriers are associated with risk for PD (Aharon-Peretz et al.,
2004), this may suggest that reduced GCase activity is not solely responsible for disease
onset. Further to this, milder mutations (N370S and R496H) had similar or lower GCase
activity levels than some of the severe mutations (Alcalay et al., 2015). Correlations have
been shown with ER stress and GD severity (Ron and Horowitz, 2005), suggesting that
mutations causing severe conformational modifications and ER retention may be important
in disease pathogenesis and possibly PD.
The exact mechanism by which reduced GCase activity and protein levels contribute
to PD pathogenesis is not fully known but it includes α-synuclein accumulation, ER stress 
and lysosomal dysfunction. Mutations in the SNCA gene, that encodes α-synuclein, lead to 
the qualitative and quantitative abnormalities of the protein and increased secretion and
accumulation of native α-synuclein, both which are associated with PD (Lin and Farrer, 
2014). Mutations in GCase, including the common N370S, L444P and D409H variants,
cause a significant increase in α-synuclein levels in GD models, particularly in neurites 
(Cullen et al., 2011; Sardi et al., 2011). Accumulation of α-synuclein has also been observed 
in the cortical neurons and whole brains from GBA knock-out mice (Mazzulli et al., 2011;
Osellame and Duchen, 2013), with GCase activity reduced in PD brain regions associated
with increased α-synuclein levels (Murphy et al., 2014). In SH-SY5Y cells, the specific 
inhibition of GCase, through conduritol B epoxide (CBE) administration, significantly reduced
GCase activity but also caused an accumulation of α-synuclein (Cleeter et al., 2013), and 
SCNA overexpression resulted in a marked reduction in GCase activity in this cell line (Gegg
et al., 2012). This suggests that GCase activity and mutations may be involved in PD
pathogenesis through enhancing α-synuclein accumulation. This is supported as analysis of 
PD-patient derived CSF demonstrated that patients carrying the N370S GBA mutation
displayed the highest levels of both total and oligomeric α-synuclein which correlated with 
much lower GCase activity when compared to non-carriers (Parnetti et al., 2014).
When mutations in GCase arise, the protein may unfold in the ER and activate the unfolded
protein response (UPR) and ER-associated protein degradation (ERAD) to decrease the
burden of the ER and refold the proteins. When the misfolded proteins cannot be refolded,
they are degraded by the UPS. Persistent activation of the UPR and ERAD causes ER
stress (Doyle et al., 2011), which has been seen in PD brains. Mutant GCase has been
reported to induce ER stress (Gegg et al., 2012). Mutations in the GBA gene cause improper
folding of the GCase protein, its retention in the ER and disturbances in its trafficking (Ron
and Horowitz, 2005). In fact, the levels of co-localisation of GCase and ER markers correlate
well with disease severity. Mutations including homozygous N370S, biallelic L444P (Type 2)
and homozygous D409H (Type 3) all cause severe GD and display high levels of GCase
retention in the ER. On the other hand, mild forms of GD arising from both homozygous or
biallelic N370S mutations exhibit much less ER retention (Ron and Horowitz, 2005). As just
mentioned, homozygous N370S mutations can cause both severe and mild GD. A high
degree of variation in disease severity between individuals with the same N370S/N370S has
been reported, with some cases associated with high risk of early disease onset and severe
clinical manifestations (Fairley et al., 2008; Zhang et al., 2012). This phenotypic
heterogeneity may arise through variable degrees of ER retention. In GD fibroblasts clinically
mild N370S phenotypes have variable GCase endoglycosidase-H sensitivity compared to
those with severe N370S GD (Ron and Horowitz, 2005), suggesting the differences in
clinical severity may be due to variable degrees of ERAD and protein processing. Several
intracellular proteins involved in mediating protein trafficking, including heat shock proteins
(Bukau et al., 2006; Chaudhuri and Paul, 2006), may also influence disease severity by
affecting the pathway with different efficiencies. Altered calcium handling and lysosomal
dysfunction may also play a role in influencing differences in disease severity between
individual with the same mutation (Fernandes et al., 2016). L444P mutant GD-patient
derived fibroblasts also recently exhibited high levels of ER stress, indicating that L444P-
GCase undergoes extensive ERAD (Bendikov-Bar et al., 2011). The activation of these
processes through reduced GCase activity and accumulation can disturb the lysosomal
degradation pathways responsible for the clearance of α-synuclein and defective 
mitochondria (Bae et al., 2015; Osellame and Duchen, 2013). It has also been proposed that
accumulation of GlcCer in the lysosome may contribute to lysosomal dysfunction (Gegg et
al., 2012). GlcCer may also interact directly with α-synuclein oligomers to stabilise them and 
induce their amyloid formation (Mazzulli et al., 2011). Another possible mechanism in which
GCase protein mutations increase the accumulation of α-synuclein may be through 
interactions between the two proteins. The molecular interaction between GCase and SNCA
is yet to be fully elucidated, however they have been shown to directly interact in acidic
conditions. Several charged surface residues that lie between domains II and III of the
GCase protein are thought to interact with the c-terminal of α-synuclein, however when the 
N370S mutation was introduced there was a marked drop in affinity for α-synuclein (Yap et 
al., 2011). It has also been reported that this interaction may be mediated at membrane
sites, forming a membrane-bound complex with α-synuclein which subsequently inhibits 
GCase activity further (Yap et al., 2013). The pathogenesis of PD includes reduced GCase
activity, α-synuclein accumulation and impaired lysosomal and mitochondrial function and 
thus GBA mutations may exacerbate these factors to influence PD onset.
Specific disease-causing mutations and the acid-β-glucosidase structure 
Disease-causing mutations are spread across the whole GCase protein (Figure 5a).
Three known GD causing mutations, H311R, A341T and C342G, are located in the active
site area close to the catalytic dyad, suggesting they may have a direct negative effect on
catalytic activity. H311R occurs close to the beginning of loop 3 and forms a hydrogen bond
with the catalytic residue Glu 235, which may explain the manifestation of severe GD. As
mentioned earlier, Cys 342 is a free cysteine which lines the active site and is thought to be
involved in preserving an active enzyme (Liou et al., 2006) thus mutations on this residue
(including C342G and C342T) cause severe disease (Beutler et al., 2005). Other mutations
in the active site include the common GD-causing substitutions R120W and D127V, which
are both important residues that line the active site pocket (Figure 2b), with R120W forming
a hydrogen bond with Glu 340 and to stabilise the catalytic dyad. Interestingly, D127V
mutant GCase proteins have an altered pH sensitivity, with their optimal pH for catalysis
shifting to 0.4-0.6 (Liou et al., 2006), suggesting this residue may also be important for
stabilising active site interactions. The GD-causing 84GG insertion also occurs near the
active site region (Figure 5) and has been associated with PD (Aharon-Peretz et al., 2004).
This mutation is a frameshift mutation, which often lead to premature stop codons, severely
truncated or abnormally long proteins (Latchman, 1998), which are likely to be non-functional
and thus GCase activity would be very low to completely abolished.
As well as occurring near the active site, disease-causing mutations can be found on
residues across all three domains (Figure 5). The neuronopathic GD-causing substitution,
D409H is located on the helical segment between two strands in domain I and participates in
hydrogen bond interactions with Ser 97. The replacement histidine and the adjacent proline
residues (Pro 98-99) result in a very rigid structure preventing the histidine participating in
similar hydrogen bonding (Lieberman, 2011) and reducing the structural stability of domain I.
This mutation has also been associated with early-onset PD (Duran et al., 2013). The V394L
mutation causes severe GD, and resides in domain I on loop 2. The Val 394 residue forms
part of the ring of important residues surrounding the entrance to the active site and thus the
substitution with a bulky leucine side chain may perturb the lining of the active site (Dvir et
al., 2003), limiting access through conformational changes. Another severe disease-causing
mutation is V15L. Val 15 is in the hydrophobic pocket of domain I, made up on Phe 9, Leu
354 and Tyr 414, therefore replacement with a bulky leucine side chain may result in steric
clashes (Liou et al., 2006). This mutation is also located near the N-glycosylation site Asn19
and the disulphide bridges (Figure 5) so may interfere with their formation or stability. In
domain II, far from the active site, the common R496C mutation occurs to cause mild GD.
This residue is thought to be important in stabilising the domain’s n-terminus through side
chain interactions and when disrupted the GCase structure becomes flexible and less stable
(Brumshtein et al., 2010). R463C is also located in the Ig-like domain, away from the active
site, and causes severe GD (Dvir et al., 2003) as well as increasing the risk for early-onset
PD (Duran et al., 2013). The large number of mutations in both domains I and II indicates
that these domains may have important regulatory or structural roles.
An interesting mutation is the E326K substitution, located in domain III. This mutation
is reported to be the most common PD-associated GBA mutation, however patients carrying
homozygous E326K mutation present no clinical features of GD (Duran et al., 2013). When
homozygous, E326K causes only a subtle reduction in GCase enzymatic activity (Chabas et
al., 2005; Horowitz et al., 2011; Liou and Grabowski, 2012), which may explain why the
mutation does not lead to GD. However when present on the same allele with another GBA
mutation, including L444P and N370S, there is almost complete loss of enzyme activity
(Chabas et al., 2005; Liou and Grabowski, 2012). This further strengthens the association of
GBA and PD.
The L444P and N370S mutations do not act by removing key catalytic residues but
likely cause destabilisation of the native GCase structure resulting in its degradation
(Lieberman et al., 2007). The L444P mutation results in an unstable enzyme found to have
little or no residual activity (Grace et al., 1994; Pastores and Hughes, 1993). It has been
reported to account for over 40% of mutations in studies with Type 2 (Stone et al., 2000) and
Type 3 GD patients (Koprivica et al., 2000), with severe neurologic manifestations. It occurs
in the hydrophobic core of domain II at the interface with the TIM barrel (Figure 5a). Although
severe and associated with PD, L444P is a considerable distance from the active site
suggesting there may be an important function for domain II, potentially offering structural
support or binding Saposin C. The substitution of leucine to proline causes rigidity in the
protein backbone and may disrupt the hydrophobicity of domain II, altering domain function
(Lieberman, 2011). In addition to improper folding and domain disruption, impaired
glycosylation may be linked to the L444 residue because, as mentioned previously,
occupancy of the Asn 19 N-glycosylation site increases stability in this region (Dvir et al.,
2003). Therefore, increasing glycosylation of L444P GCase may rescue instability of the
mutant protein. Leu 444 is also located close to the Asn 462 glycosylation site (Figure 5a),
so may induce alterations in its occupancy or stability. The N370S mutation also associates
with PD. It occurs on the longest α-helix at the interface of domains II and III (Figure 5a), 
hence too far from the active site to participate directly with catalysis, suggesting the
mutation must have some structural impact. As discussed earlier, mutant analysis has
shown that Asn 370 has an indirect role in maintaining the conformation of the active site
(Grace et al., 1994), as well as being involved in catalytic stability, by stabilising the helical
conformation of loop 3 upon substrate binding via hydrogen bond networks (Lieberman et
al., 2007). Therefore when a serine residue replaces this asparagine and the distance from
loop 3 increases, destabilisation of loop 3 occurs and impairs the ability of GCase to bind the
substrate (Lieberman et al., 2007). As the N370S variant results in a much milder clinical
phenotype than the L444P variant, one would expect that the structural alterations of GCase
are much more severe when the L444P mutation occurs.
Figure 5. Disease-causing mutations in acid-β-glucosidase (diagram created using PYMOL 
(http://www.pymol.org)). (A) The common mutations associated with Gaucher disease, mapped onto
the acid-β-glucosidase structure (PDB code 3GXD). Mutations are depicted by red spheres; N-
glycosylation sites are blue spheres; free cysteines are orange spheres and disulphide bridges are
yellow spheres. The catalytic residues are ball-and-stick models. Domain I is pink, domain II is
green and domain III is teal. (B) Loop 3 conformation in native and N370S acid-β-glucosidase. Loop 
3 is presented as blue. (i) native acid-β-glucosidase at neutral pH with extended loop (PDB code 
3GXF) (ii) native acid-β-glucosidase at acidic pH showing helical conformation (PDB code 3GXD) 
(iii) N370S acid-β-glucosidase at neutral pH showing extended conformation (PDB code 3KEH) (iiii) 
N370S acid-β-glucosidase at acidic pH showing extended conformation (PDB code 3KE0).
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Structure of N370S mutant acid-β-glucosidase 
It is difficult to correlate changes in structure with disease severity as, to date, there
are no structures of mutant GCase available except for N370S. As mentioned, due to the
mild phenotype seen in N370S patients, it may be assumed that only minor changes to the
GCase structure and catalytic activity occur. Analysis of both the x-ray structure (Wei et al.,
2011) and molecular dynamic simulations (Offman et al., 2010) of N370S GCase has
provided insight into how this mutation causes disease. The structure of wild-type and
mutant GCase are virtually indistinguishable at both acidic and neutral pH however N370S
GCase has been reported to have increased thermostability (Wei et al., 2011) and reduced
RMSF values (Offman et al., 2010), indicating higher structural stability, at neutral pH,
supporting the revelation that in N370S mutant protein the pH optima shifts from 4.5 to 6.4
(Steet et al., 2006). Both papers are in agreement that the biggest change is the orientation
of loop 3. As discussed earlier, at neutral pH loop 3 adopts an extended conformation which
transitions to a helical conformation in acidic conditions for catalysis, as shown in Figure 5b.
However, only one conformation for loop 3 is observed in N370S GCase, presenting only in
the extended conformation across the pH range (Offman et al., 2010; Wei et al., 2011) again
providing evidence that the Asn 370 residue is important in stabilising the helical turn of loop
3. The comparison of N370S and native GCase loop 3 conformation is shown by Figure 5b.
The substitution with serine alters the hydrogen bond network as Trp 312 can no longer
interact with Ser 370, as it would with Asn 370, at acidic pH to stabilise the helical
conformation and instead forms hydrogen interactions with Ser 366 on the same helix. This
results in a rigid loop 3 structure, potentially reducing substrate binding, access to the active
site and catalytic dyad integrity. Several residues were also reported to have different
orientations, including some charged and polar residues of the flexible loops in domain II and
residues located in the active site suggesting there may be some change in loop behaviour
or active site conformation (Offman et al., 2010). The N370S GCase variant has been
reported to have significantly reduced interactions with Saposin C (Salvioli et al., 2005),
suggesting that the residues involved may be important in binding the protein. Interestingly,
molecular dynamics simulation predicts a destabilisation in loop 1 which is not observed in
the x-ray structure (Offman et al., 2010; Wei et al., 2011). This analysis has provided great
insight into how mutations outside of the active site region may be detrimental to GCase
protein structure and show that overall the N370S structure is much more rigid, with less
flexibility and thus prevention of loop 3 helical conformation.
Therapeutic application
Understanding the protein structure of GCase will help in the development of novel
treatments for GD and PD. Currently, substrate replacement therapy (SRT) and enzyme
replacement therapy (ERT) are popular therapeutic approaches to treat GD. SRT inhibits the
synthesis of the GlcCer substrate through selective inhibition of GlcCer synthase to alleviate
the consequences of GBA mutations (Jung et al., 2016; Marshall et al., 2016). ERT utilises
recombinant GCase enzymes, however its inability to cross the blood-brain-barrier (BBB) is
a major drawback as the neurological symptoms associated with GBA mutations remain
untreated (Maegawa et al., 2009). Recently, small molecular chaperones for GCase have
been developed which can cross the BBB and potentially alleviate these symptoms.
Molecular chaperones have been designed in order to bind to GCase to facilitate proper
folding and increase stability, catalytic activity and lysosomal translocation (Bendikov-Bar et
al., 2011; Lieberman et al., 2009; Maegawa et al., 2009). A very recent study has suggested
the beneficial action of such compounds arises through increasing GCase protein
stabilisation and resistance to breakdown by lysosomal proteases (Ben Bdira et al., 2017).
Administration of small molecular chaperones have been reported to increase lysosomal
GCase activity and trafficking in wild-type and GBA mutant fibroblasts, including N370S and
L444P variants, as well as in L444P transgenic mice (Khanna et al., 2010; Lieberman et al.,
2007; Sawkar et al., 2006). One such molecular chaperone is ambroxol, a pH-dependant
inhibitor of GCase, with the ability to enhance the stabilisation and trafficking of the mutated
form. This chaperone binds GCase at a region near the active site (residues 243-249, 310-
312 and 386-200) and stabilises the protein in its native-state (Maegawa et al., 2009).
Ambroxol is also thought to work through activation of the CLEAR (co-ordinated lysosomal
expression and regulation) network, which is regulated by TFEB (transcription factor EB) to
control the transcription of genes encoding proteins involved in lysosomal function and
biogenesis, including the GBA gene (McNeill et al., 2014). Although reported in fibroblasts
(McNeill et al., 2014), there seemed to be no ambroxol-mediated effect on TFEB in
transgenic GBA mice (Migdalska-Richards et al., 2016). Ambroxol administration reversed
the effects of GBA mutations (including R120W, N370S and L444P) in patient-derived
fibroblasts (Bendikov-Bar et al., 2011; Luan et al., 2013; McNeill et al., 2014; Sanchez-
Martinez et al., 2016). Recently, neural crest stem cell (NCSC) models for PD and GBA
mutations have also demonstrated efficacy for ambroxol. NCSCs were differentiated into
dopaminergic neuronal cell lines harbouring wild-type GBA or N370S/+ GBA mutations.
Reduced GCase activity and protein levels, increased α-synuclein accumulation and 
defective lysosomal autophagy were observed in the GBA mutant cell lines, all of which were
reversed by treatment with ambroxol (Yang et al., 2017). In addition to NCSCs, α-synuclein 
accumulation has been reduced by ambroxol in SH-SY5Y overexpressing cell lines and
transgenic SNCA/SNCA mice (McNeill et al., 2014; Migdalska-Richards et al., 2016). In
Drosophila fly models ambroxol reversed GBA mutant effects, including ER stress, reduced
GCase activity and motor defects (Maor et al., 2016; Sanchez-Martinez et al., 2016; Suzuki
et al., 2013). Transgenic mice carrying the L444P/+ gene and wild-type mice also had
increased GCase activity in response to ambroxol (Luan et al., 2013; Migdalska-Richards et
al., 2016), the same was observed recently in healthy nonhuman primates (Migdalska-
Richards et al., 2017).
Ambroxol is an inhibitory chaperone rendering GCase inactive when in this complex. Non-
inhibitory chaperones may be a more attractive option as they may additionally stimulate the
residual enzyme activity (Jung et al., 2016). A novel non-inhibitory small molecular
chaperone has shown promise in improving lysosomal translocation, activity and protein
levels of GCase in induced pluripotent stem cell (iPSC) lines from GD patients with and
without PD. Levels of α-synuclein were also reduced in PD patient cells (Aflaki et al., 2016). 
As the majority of GBA mutations are missense these small molecular chaperones are an
attractive therapy option as the protein is still produced, just misfolded. Thus, if we
understand more about how individual mutations alter the protein structure we can develop
more efficacious mutation-specific chaperones to bind. This therapy however, does not
improve the defects associated with the 84GG mutation as no mature GCase protein is
expressed (Maor et al., 2016).
Concluding remarks
In this review we have discussed the x-ray structure of the GCase protein and known
important residues, and also began to explore the link between Gaucher disease-causing
mutations and structural aspects of the protein. Several mutations in GBA cause a spectrum
of GD variants, with many of these associated with the onset of PD. However, it is yet to be
fully elucidated how mutations in the GCase protein contribute to PD pathogenesis. It is not
yet understood how specific mutations alter the protein structure and disease severity, as
well as impact the risk of developing PD. Since the initial depiction of the x-ray structure of
GCase the potential for analysis of this relationship has arose however, more understanding
of specific residues and structural aspects of GCase and their roles is imperative. For
example, further insight into local conformational stability and glycosylation site occupancy
may lead to a new avenue in GD treatments to rescue mutant protein stability. Further
analysis through site-directed mutagenesis would reveal more important residues and
potentially shed light on the importance of domains I and II or reveal whether loop 3 is in fact
critical for catalysis. Generation of the x-ray structure for most of the common GD mutations
would be ideal. This would show the effect that each mutation has on the protein structure,
and potentially unveil specific structural alterations that could be targeted for therapy.
Analysis of the N370S mutant protein x-ray structure has allowed improved small molecules
to be developed to bind to known N370S alterations and help restore enzyme functionality. It
may be difficult to obtain the x-ray structure of all mutants however, as some produce
unstable proteins. In conclusion, the GCase protein structure is very complex and houses
several known important residues with many more residues likely having an unknown key
role. The location of disease mutations loosely correlates with alterations in structural
stability and catalytic activity however, it remains difficult to predict disease severity based
on mutation location as understanding of how the structural defects caused by specific
mutations contribute to disease is lacking.
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 Mutations in GBA are associated with increased risk of Parkinson’s disease.
 Different mutations may disrupt specific structural aspects of GBA protein.
 Altered conformations may explain differential PD risk associated with mutations.
